Either way, it doesn't bother me at all, I am confident that we have the float locked to the extent we can control it, and I would love the opportunity to buy more shares like the .047s I picked up yesterday.

I think the TA on this stock is great, and the LII observations the team posts throughout the day provide valuable insight, as I do not have level II yet.

I have never met a more honest or genuine group of fellow investors to be on a stock with. I think we should continue to expect more volatility, with the trend higher. We will pick up some oddballs and wingnuts along the way, it is a free country, but I remain convinced the ratio of solid longs to nutjobs on CDIV will continue to move in our favor due to the quality fundamentals.

Someone is selling.

Oops! Buck fever happens.

How was the hunting, Joe?

that's why Monk is the MAN

Don't beat yourself up Skunk. You're on the 'right side of history'! And we are going to make not only history, but significant press, and enough money to go around.

Geewwwwd Morrrrniiiiinnnnngggggg.... CDIV'ers!

Wishing you all the best of days.

Do share!

Hold strong tomorrow gents. NITE can pry the shares from my cold dead fingers.

:) that comes with the package!

I am with you!

May we all make a bundle. I am jealous of Monk's trading station and want one. Or 6.

Buying, not selling. Feel lucky about the .047's. First time I have ever been the low buy of the day on any stock.

Thank you for the shares at .047

Notice to APWR investors: APWR 5-star Investors Group is a representative group of retail investors in APWR, representing over 300mm long shares. APWR 5-star Investors Group members represent some of the best retail long due diligence on APWR I've seen. The group will be represented on APWR's upcoming conference call. For more information on APWR 5-star Investors Group, email APWR5StarInvestorsGroup@yahoo.com

APWR detailed writeup from website on Obama team meeting.

http://www.lngkny.org/english/gnly-show....

At 2:pm on Nov.16, 2009, Beijing China World hotel, Deputy mayor of Shenyang Mr. Yang Yazhou, deputy secretary in general of Shenyang municipal government Mr. Gu Shaoqing, A-Power’s chairman & CEO Mr. Lu Jinxiang and others participants met with Mr. Ron Kirk, trade representative at President Obama’s China delegation. As the US trade representative and member of Obama’s cabinet, he works as the major trade consultant for the president and takes on the roles of trade coordinator and speaker for US. Also being at the meeting there were Mr. Ma Lixin and Ms. Lu Ming, deputy director and vice division head both from Shenyang Foreign Affairs Office, Mr. Lin Haibo, deputy director of Hunnan Development Zone,Mr. John Shen Lin COO of A-Power and Ms. Wang Guijuan VP of Liaoning High-tech.
On this meeting, deputy mayor of Shenyang Mr. Yang Yazhou firstly introduced to Ron Kirk about situations of Shenyang Power Group, expressing his assent on the JV cooperation between US Renewable and SPG to co-develop the 600 MW wind farms in West Texas. Mayor Yang also pointed out that Shenyang municipal government would grant its full support and assistance both in policy and economically for SPG entering into US market. As the first equipments-manufacturing enterprise in Shenyang entering into US, SPG should become a famous brand name representing Shenyang. Yang warmly invited Ron Kirk to visit Shenyang at his convenience.
Representative Ron Kirk expressed a welcome attitude towards China investing in US especially in the field of green energy. In the past five years, China has become the country whose direct investment in US grew the fastest, with US anticipating more resources inputs from China into new projects in US.
Ron Kirk expressed his welcome attitudes towards co-investing by US Renewable and SPG to build the 600 MW wind farms in West Texas. As being the former mayor of City of Dallas and long-time resident in Texas, Representative Ron Kirk feels excited about the project located in West Texas. President Obama also holds an affirmative attitude towards Sino-US cooperation in the field of green energy and other energy sectors.
With regards to the planned 320,000 sq. feets wind turbine assembly plant in US, Ron Kirk has an approving view too. With a total production capacity of 1100MW（1.1GW）, the plant will bring the employment opportunities to the local people in US. The construction of this wind farm project will symbolize Shenyang’s equipments-manufacturing industry starts to occupy the US market. Through this mutual investment between the two countries with this project, the friendship between the two nations will be strengthened too.
After the talk, A Power, SPG and US renewable signed an intent agreement which foresees a new history of cooperation in new energy field between the two nations.

I am volunteering to be the moderator of this board as a representative of APWR's 5 star investor group, who represent 300mm shares.

I absolutely agree. I think this group of folks is great. Let's nail this float down, gents.

I am in!

CDIVrs: Morning all. I heard something completely provocative this morning! Someone told me that the CDIV IHub group was a dangerously well-funded group of investors in the process of an overwhelming float lockdown. Thought I would pass it on- sounds pretty scary!

I am very glad to have found you guys after the better part of a year picking through the excrement on yahoo message boards.

SAIF deserves a good run. I am assured the days of this company trading at net asset value are vanishing, and that an aggressive float lockup is underway to base us to $1.50.

Great info on the filing, thanks for posting this. I'm holding my breath on the filing, and being late pisses me off some.

Monk is back, and sanity returns. Noted.

Amen

Good morrrrrrninnnnnng... CDIV board!

Did we all take our fiber pills last night?

Looking forward to the next leg north after this healthy retrace.

APWR- Joe, I know you stated previously you didn't care much for these guys. And, clearly, APWR's massive plans will require a lot of cash to pull off. However, the new APWR 2.7mw turbine seems to be very well received, and it seems the 2.5mw class turbine will be a higher margin subset of the wind power space. With the biggest wind turbine factory in China and a GE gearbox joint venture, given the news of late, does APWR warrant a new look? Thanks and good luck with your deer hunting.
TNZ

disclosure long APWR

APWR building wind manufacturing in the USA.

http://www.prnewswire.com/news-releases/the-us-renewable-energy-group--a-power-energy-generation-systems-ltd-announce-plans-to-build-a-wind-energy-turbine-production-and-assembly-plant-in-the-united-states-70244717.html

APWR building wind manufacturing in the USA.

Hope everyone saw this last night. 2010 will be a very interesting year for APWR.

http://www.prnewswire.com/news-releases/the-us-renewable-energy-group--a-power-energy-generation-systems-ltd-announce-plans-to-build-a-wind-energy-turbine-production-and-assembly-plant-in-the-united-states-70244717.html

To my CDIV friends, I humbly recommend you take a couple of Joe Natural's "ADVIL" in this situation: Hold half your position long, and hold half as trading shares. Guaranteed to regrow hair too!

drop from .08 high to .05 does not represent an abnormal retrace. This is within the range of a fibonacci retrace from a high. Not sure I can hold you all, but I'm going to continue buying in the .05's.

Had a small fill at .058

No question, we need tax reform, Hank, and a society that rewards productivity. When was the last time you shopped your $2k per employee per month health plan? How'd you get hit with 60% personal taxes after paying 48% on the business?

Sure. I'm wondering if io_io will find one.

Thanks K from Cal.

I'm looking for that info too. Ruby at OPXA said no webcast would be available- so I'm looking for a transcript, whatever I can get my hands on.

I don't have a side, Bagger. I'm just one human here doing the best I can. The use of rhetoric in this country is at a level that I can only describe as pathetic. May math prevail.

Come on, Burp. I called you out for posting bad data. It wasn't an attack on your person, and you don't have to justify it to me.

I can also. With OPXA's efficacy and safety data, (admittedly from the last skewed study, where the placebos were healthier than the test subjects), hard to imagine Tovaxin as solely IP doesn't have a market value of at least 100mm.

Burp, I read your stock posts with a relative degree of interest, and appreciate the thought you put into them. The hypocrisy I see here is comparing the lack of due diligence you put into posting this rubbish.

If, because of your political, socioeconomic, or cultural bias, you don't like Michelle Obama, fine. But the data persented here is of the same quality as most of the radical right spew campaigns I see circulated by dejected conservatives.

If the GOP in America has a relevant near term future it will be demonstrated through positions on relevant issues.

My two cents.

In addition to the data we already know and understand regarding Tovaxin's emerging safety and efficacy profile, I noted a few things from the Merriman presentation yesterday.

1. The next progress payment from Novartis will happen soon. While this progress payment is only $500k, it represents a significant milestone in the successful transfer of islet cell technology to Novartis, in a deal which is valued at up to $50 million of revenue for Opexa. This islet cell deal is wholly, completely, separate from Opexa's primary asset, Tovaxin, in which Opexa has not yet sold a single right, and retains a strong and exclusive patent position.

2. A commercial partnership for Tovaxin is proceeding well and talks are actively engaged with companies in two separate and distinct Pharma segments- those who presently have offerings in the MS pharma market and are interested in Tovaxin, and those who have strength in Neurology pharma and are interested in Tovaxin.

3. The cost of manufacturing and distribution of Tovaxin is not a constraint. These costs are well documented, will not impact margins, and are in line with the ratios found in the broader pharmaceutical market.